A monophasic combined oral  contraceptive study

NOMAC-E2, also known as Zoely® and Stezza®, has been registered and approved in more than 50 countries worldwide. NOMAC-E2 is an investigational contraceptive in the United States (US), meaning it has not been approved for sale by the Food and Drug Administration (FDA) in the US. Therefore its use in this study is considered experimental.

To qualify to participate you must
  • be a female 18-35 years old
  • be at risk for pregnancy (heterosexual, vaginal intercourse at least once/month)
  • not be desiring pregnancy
  • otherwise good general health
  • have a history of regular menstrual cycles (21-35 days)

Compensation provided to Qualified participants. Study includes free study-related exams, pap, STI testing, contraception. Participants are asked to complete daily diary throughout 14 month study.
Combined hormonal oral contraceptives (CHCs) are one of the most common birth control methods used by women. The main goal of the development of CHCs is the demonstration of  inhibition of ovulation, good vaginal bleeding pattern, and safety.

The best way to find out more information or to get started, is to contact us using the confidential inquiry form below:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.